



Novo Holdings

Novo Holdings is a **world-leading life science investor** with offices in Copenhagen, London, Boston, San Francisco, Singapore, and Shanghai. We invest in the US, Europe and Asia, across the life sciences continuum from very early-stage Seed investments, through the Ventures and Growth stages and into Principal (buyout) investments, collectively named **Life Science Investments**.


In addition to investing directly within life sciences, Novo Holdings also manages a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets, collectively named **Capital Investments**. Novo Holdings is also the controlling shareholder of Novo Nordisk and Novonosis, collectively the **Novo Group**.

Novo Holdings' sources of funds are the dividends and share repurchases from the Novo Group companies, and the returns from both Life Sciences and Capital Investments. The annual capital deployment target across the life sciences investment platforms is around EUR 2.7 billion (USD 3 billion). Over the past 5 years Novo Holdings has deployed EUR 8.3 billion (USD 9.2 billion) into life sciences companies.


Novo Holdings was incorporated in 1999 to manage the wealth and the assets of the Novo Nordisk Foundation, with a focus on improving people's health and the sustainability of society and the planet.

Novo Holdings structure

Our investment returns support the grant giving activities of the Novo Nordisk Foundation, which has donated more than EUR 5.0 billion (USD 5.5 billion) to scientific, social, and humanitarian causes since 2018.




Novo Nordisk Foundation philanthropic grants and investments outlook 2030



*Known as Novonosis following the merger with Chr. Hansen

Novo Holdings at a glance




Numbers based on Novo Holdings' Performance Report 2023


Novo Holdings Investment Portfolio at a glance

Since 2000, Novo Holdings has invested in more than 350 companies across the globe. The snapshot reflects the split of our Investment Portfolio and Life Sciences Investment Portfolio at year-end 2023.


Investment Portfolio split by Life Science Investments and Capital Investments



Investment Portfolio split by asset class



Novo Holdings Life Science Investment Portfolio Split by subsector, number of companies



Novo Holdings Life Science Investment Portfolio Split by subsector, USD

